Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder with incomplete penetrance. It is caused by mutations in sarcomeric genes, which codes for beta-myosin heavy chain (MYH7) and myosin binding protein C (MYBPC3). HCM genotyping help in understanding the role of genotyping in the management of several other cardiovascular disorders. Various problems are associated with genotyping hypertrophic cardiomyopathy. These are presence of multiple mutations, etc. Family screening for all HCM patients may allow early identification of disease. Strategies for screening for first-degree relatives of HCM patients: (i) clinical screening; and (ii) genotyping. Genotyping approach can be used if a pathogenic mutation is found in the proband. Limitations of screening are also discussed.